Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has adjusted the repurchase price of its 2022 restricted stock incentive plan to 6.48 CNY per share [1][4]. Summary of Related Sections 2022 Restricted Stock Incentive Plan Overview - On July 29, 2022, the company approved the 2022 restricted stock incentive plan, with a grant price of 6.98 CNY per share for 6,775,183 shares to 175 incentive targets [2]. - The plan underwent several approvals and adjustments throughout 2022 and early 2023, including the cancellation of 40,000 shares and a reduction in total share capital from 316,600,050 to 316,560,050 shares [2]. Adjustments to Repurchase Price - The repurchase price was adjusted based on the company's profit distribution plan, which includes a cash dividend of 2 CNY per 10 shares for the total share capital of 316,357,550 shares [4]. - The adjustment formula used was P = P0 - V, where P0 is the original grant price and V is the dividend per share [4]. Impact of Adjustments - The adjustment complies with relevant laws and regulations and will not materially affect the company's financial status or operating results [5]. - The independent directors and supervisory board have agreed to the adjustment, and legal opinions confirm its compliance with regulations [5].
哈三联调整2022年限制性股票激励计划回购价格至6.48元/股